At the next stage of the work, in the formed sample of patients, using the Accel-Amplicon BRCA1, BRCA2, and PALB2 panel, tumor samples were screened before and after chemotherapy for the presence of mutations in the studied genes. This evidence concerns the gene BRCA1 and neoplasm.